|
1
|
Yuasa Y: Control of gut differentiation
and intestinal-type gastric carcinogenesis. Nat Rev Cancer.
3:592–600. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dalerba P, Cho RW and Clarke MF: Cancer
stem cells: models and concepts. Annu Rev Med. 58:267–284. 2007.
View Article : Google Scholar
|
|
4
|
Nishikawa S, Konno M, Hamabe A, et al:
Aldehyde dehydrogenase high gastric cancer stem cells are resistant
to chemotherapy. Int J Oncol. 42:1437–1442. 2013.PubMed/NCBI
|
|
5
|
Takaishi S, Okumura T, Tu S, et al:
Identification of gastric cancer stem cells using the cell surface
marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang L, Levi E, Zhu S, Du J and Majumdar
AP: Cancer stem cells biomarkers in gastric carcinogenesis. J
Gastrointest Cancer. 44:428–435. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu WD, Zhang T, Wang CL, et al:
Sphere-forming tumor cells possess stem-like properties in human
fibrosarcoma primary tumors and cell lines. Oncol Lett.
4:1315–1320. 2012.PubMed/NCBI
|
|
8
|
Salerno M, Avnet S, Bonuccelli G, et al:
Sphere-forming cell subsets with cancer stem cell properties in
human musculoskeletal sarcomas. Int J Oncol. 43:95–102.
2013.PubMed/NCBI
|
|
9
|
Tian T, Zhang Y, Wang S, Zhou J and Xu S:
Sox2 enhances the tumorigenicity and chemoresistance of cancer
stem-like cells derived from gastric cancer. J Biomed Res.
26:336–345. 2012. View Article : Google Scholar
|
|
10
|
Jiang J, Zhang Y, Chuai S, et al:
Trastuzumab (herceptin) targets gastric cancer stem cells
characterized by CD90 phenotype. Oncogene. 31:671–682. 2012.
View Article : Google Scholar
|
|
11
|
Yang L, Ping YF, Yu X, et al: Gastric
cancer stem-like cells possess higher capability of invasion and
metastasis in association with a mesenchymal transition phenotype.
Cancer Lett. 310:46–52. 2011.PubMed/NCBI
|
|
12
|
Chen L: Co-inhibitory molecules of the
B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol.
4:336–347. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong H, Strome SE, Salomao DR, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen XL, Cao XD, Kang AJ, et al: In situ
expression and significance of B7 costimulatory molecules within
tissues of human gastric carcinoma. World J Gastroenterol.
9:1370–1373. 2003.PubMed/NCBI
|
|
15
|
Lu B, Chen L, Liu L, et al:
T-cell-mediated tumor immune surveillance and expression of B7
co-inhibitory molecules in cancers of the upper gastrointestinal
tract. Immunol Res. 50:269–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu C, Zhu Y, Jiang J, et al:
Immunohistochemical localization of programmed death-1 ligand-1
(PD-L1) in gastric carcinoma and its clinical significance. Acta
Histochem. 108:19–24. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shi F, Shi M, Zeng Z, et al: PD-1 and
PD-L1 upregulation promotes CD8(+) T-cell apoptosis and
postoperative recurrence in hepatocellular carcinoma patients. Int
J Cancer. 128:887–896. 2011. View Article : Google Scholar
|
|
18
|
Wang L, Qian J, Lu Y, et al: Immune
evasion of mantle cell lymphoma: expression of B7-H1 leads to
inhibited T-cell response to and killing of tumor cells.
Haematologica. 98:1458–1466. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sznol M and Chen L: Antagonist antibodies
to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human
cancer-response. Clin Cancer Res. 19:55422013. View Article : Google Scholar
|
|
20
|
Azuma T, Yao S, Zhu G, et al: B7-H1 is a
ubiquitous antiapoptotic receptor on cancer cells. Blood.
111:3635–3643. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Curiel TJ, Wei S, Dong H, et al: Blockade
of B7-H1 improves myeloid dendritic cell-mediated antitumor
immunity. Nat Med. 9:562–567. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eppihimer MJ, Gunn J, Freeman GJ, et al:
Expression and regulation of the PD-L1 immunoinhibitory molecule on
microvascular endothelial cells. Microcirculation. 9:133–145. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamazaki T, Akiba H, Iwai H, et al:
Expression of programmed death 1 ligands by murine T cells and APC.
J Immunol. 169:5538–5545. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang P, Su DM, Liang M and Fu J:
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1)
surface expression in breast cancer cells and promote
PD-L1-mediated T cell apoptosis. Mol Immunol. 45:1470–1476. 2008.
View Article : Google Scholar
|
|
25
|
Tao K, Wu C, Wu K, et al: Quantitative
analysis of promoter methylation of the EDNRB gene in gastric
cancer. Med Oncol. 29:107–112. 2012. View Article : Google Scholar
|
|
26
|
Leng Z, Tao K, Xia Q, et al: Kruppel-like
factor 4 acts as an oncogene in colon cancer stem cell-enriched
spheroid cells. PloS One. 8:e560822013. View Article : Google Scholar
|
|
27
|
Kim YS, Park GB, Lee HK, et al:
Cross-linking of B7-H1 on EBV-transformed B cells induces apoptosis
through reactive oxygen species production, JNK signaling
activation, and fasL expression. J Immunol. 181:6158–6169. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Radziewicz H, Ibegbu CC, Fernandez ML, et
al: Liver-infiltrating lymphocytes in chronic human hepatitis C
virus infection display an exhausted phenotype with high levels of
PD-1 and low levels of CD127 expression. J Virol. 81:2545–2553.
2007. View Article : Google Scholar :
|
|
29
|
Freeman GJ, Long AJ, Iwai Y, et al:
Engagement of the PD-1 immunoinhibitory receptor by a novel B7
family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsushima F, Yao S, Shin T, et al:
Interaction between B7-H1 and PD-1 determines initiation and
reversal of T-cell anergy. Blood. 110:180–185. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Blank C, Kuball J, Voelkl S, et al:
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell
responses in vitro. Int J Cancer. 119:317–327. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wong RM, Scotland RR, Lau RL, et al:
Programmed death-1 blockade enhances expansion and functional
capacity of human melanoma antigen-specific CTLs. Int Immunol.
19:1223–1234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Butte MJ, Keir ME, Phamduy TB, Sharpe AH
and Freeman GJ: Programmed death-1 ligand 1 interacts specifically
with the B7-1 costimulatory molecule to inhibit T cell responses.
Immunity. 27:111–122. 2007. View Article : Google Scholar : PubMed/NCBI
|
